Clinical Trial

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Terminated Phase 2

Why the trial stopped

This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

Summary

This is a randomized, controlled, open-label, multicenter clinical study to evaluate the efficacy and safety of carboplatin/cisplatin + etoposide + benmelstobart sequential benmelstobart combined with anlotinib versus carboplatin/cisplatin + etoposide + Tislelizumab sequential Tislelizumab in the first-line treatment of extensive stage small cell lung cancer.

Protocol Amendment History 5 changes

critical Trial terminated 2026-04-29

critical Reason stopped changed: — → This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns. 2026-04-29

notable Enrollment reduced: 134 -> 40 participants 2026-04-29

notable Primary completion moved earlier: 2026-10 -> 2026-04-15 2026-04-29

minor Completion moved earlier: 2027-04 -> 2026-04-15 2026-04-29

Trial Details

NCT Number	NCT06897579
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions	Extensive Stage Small Cell Lung Cancer
Enrollment	40 participants
Start Date	2025-04-07
Primary Completion	2026-04-15 (estimated)
Study Completion	2026-04-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-28